Patent US4740200A successfully refreshed from Google Patents.
US4740200A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Intravenous system for delivering a beneficial agent
Assignee: Alza Corp
•
Filing: 1985-02-15
•
Granted: 1988-04-26
•
Expires: 2005-02-15
Abstract
Abstract A formulation chamber is disclosed comprising a wall surrounding a lumen containing a device for delivering a beneficial agent. The chamber has an inlet for admitting a fluid into the chamber and an outlet for letting an agent formulation leave the chamber. The chamber is adapted for use in an intravenous delivery system for delivering an agent formulation to a patient.
Inventors
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 22:36
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
146 words
An intravenous delivery system for administering an agent formulation intravenously to a human in which the agent formulation is formulated in situ comprising in combination: (a) a container of a pharmaceutically acceptable intravenous fluid that is a carrier for the agent; (b) an intravenous administration set connected to the container for permitting the fluid to flow from the container through the administration set, the set comprising; (1) a drip chamber; (2) a tubing extending from the drip chamber to a human; and, (3) an agent formulation chamber connected into the tubing such that the intravenous fluid flows through the formulation chamber, the formulation chamber comprising a hollow housing and a rate controlled dosage means that maintains its physical and chemical integrity within the housing that is in communication with the fluid flowing through the chamber and that releases agent into the fluid at a predetermined rate.
Claim 2
Dependent Claim
146 words
An intravenous delivery system for administering an agent formulation intravenously to a human in which the agent formulation is formulated in situ comprising in combination: (a) a container of a pharmaceutically acceptable intravenous fluid that is a carrier for the agent; (b) an intravenous administration set connected to the container for permitting the fluid to flow from the container through the administration set, the set comprising; (1) a drip chamber; (2) a tubing extending from the drip chamber to a human; and, (3) an agent formulation chamber connected into the tubing such that the intravenous fluid flows through the formulation chamber, the formulation chamber comprising a hollow housing and a rate controlled dosage means that maintains its physical and chemical integrity within the housing that is in communication with the fluid flowing through the chamber and that releases agent into the fluid at a predetermined rate.
Claim 3
Dependent Claim
26 words
The intravenous delivery system according to claim 1 wherein a skin piercing means is connected to the tubing for administering the agent formulation to the human.
Claim 4
Dependent Claim
39 words
The intravenous delivery system according to claim 1 wherein the rate controlled dosage means is a solid and it releases agent at a rate that is independent of the volume rate of intravenous fluid flow through the formulation chamber.
Claim 5
Dependent Claim
17 words
The intravenous therapy system according to claim 1 wherein the formulation chamber additionally contains a filter member.
Claim 6
Dependent Claim
29 words
The intravenous delivery system according to claim 1 wherein the formulation chamber includes means for preventing the dosage means from blocking the flow of intravenous liquid through said chamber.
Claim 7
Dependent Claim
95 words
The intravenous delivery system according to claim 1 wherein the formulation chamber includes an inner enclosed pocket at least partly defined by a membrane, the membrane being the interface between the pocket and the main flow path of the fluid through said chamber, and the rate-controlled dosage means comprises a combination of the membrane and a dosage means within the pocket, whereby fluid from the intravenous fluid diffuses through the membrane into the pocket, and a solution of agent diffuses from the pocket through the membrane into the mainstream of intravenous flow through said chamber.
Claim 8
Dependent Claim
64 words
The intravenous delivery system according to claim 6 wherein the membrane is in the form of a hollow tube that extends axially through the formulation chamber, the tube defining the main flow path of intravenous fluid through said chamber, and the pocket being concentric to the main flow path defined by the outer surface of the tube and the inner surface of the housing.
References Cited (Backward Citations)
US3001525A
Cited
GB982107A
Cited
US3305446A
Cited
CH497181A
Cited
US3854480A
Cited
US3797494A
Cited
US3993073A
Cited
US3995631A
Cited
US3760984A
Cited
US3948254A
Cited
US3845770A
Cited
US3921636A
Cited
US4177256A
Cited
US3848603A
Cited
US3921635A
Cited
US3941126A
Cited
US3993072A
Cited
US4203439A
Cited
US4323457A
Cited
US4233973A
Cited
US4465471A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-26 | 1991-10-26 | 1992-04-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-26 | 1995-10-26 | 1996-04-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-26 | 1999-10-26 | 2000-04-26 | $7700.00 | Window Closed / Lapsed |